Variable | HR (95% CI) | SE | P value |
Prior autologous stem cell transplant | 0.56 (0.34 to 0.94) | 0.15 | 0.029 |
ECOG performance status | 1.23 (0.97 to 1.55) | 0.15 | 0.084 |
LDH >500 (U/L, prior to CAR T-cell infusion) | 1.52 (0.89 to 2.59) | 0.41 | 0.122 |
CRP >30 (mg/L, prior to CAR T-cell infusion) | 2.01 (1.32 to 3.07) | 0.43 | 0.001 |
Bridging therapy use | 1.18 (0.77 to 1.82) | 0.26 | 0.449 |
Receipt of tocilizumab | 0.52 (0.34 to 0.80) | 0.11 | 0.003 |
CD28 co-stimulatory domain CAR T-cell product | 0.66 (0.37 to 1.17) | 0.19 | 0.158 |
CAR, chimeric antigen receptor; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.